Limited Competition: Biospecimen Banks to support NCI National Clinical Trials Network Biospecimen Banks (NCTN Biobanks) and the NCI Early-Phase and Experimental Clinical Trials Biospecimen Bank (EET Biobank) (U24 Clinical Trial Not Allowed)
Contract Overview
Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.
AI Contract Overview
The National Cancer Institute (NCI) has issued a Limited Competition Notice of Funding Opportunity (RFA-CA-28-004) to support the continuation of two critical biospecimen banking resources: the National Clinical Trials Network (NCTN) Biobanks and the Early-Phase and Experimental Clinical Trials (EET) Biobank. The primary objective is to maintain these national resources for the collection, processing, storage, and distribution of high-quality, clinically annotated human biospecimens. These resources facilitate translational cancer research, biomarker development, and validation by providing essential specimens from NCI-funded clinical trials. The NCI intends to fund approximately six awards for fiscal year 2027, with a total estimated funding of 19 million dollars and a maximum budget of 3 million dollars in direct costs per year for a requested project period of six years. Applications will be evaluated through the NIH peer-review system based on scientific and technical merit, significance, and the adequacy of the institutional environment. Key requirements for applicants include maintaining active registrations in SAM, eRA Commons, and Grants.gov, as well as providing specific documentation regarding the current scale of operations, accomplishments, and standard operating procedures. Awardees must adhere to NCI Best Practices for Biospecimen Resources, federal human subjects regulations under 45 CFR 46, and strict cybersecurity incident reporting protocols, including notification of incidents within 48 hours of discovery. The scope of work includes managing secure informatics systems, providing specimen collection kits, and ensuring the availability of annotated biospecimens for authorized investigators.
General Info
Agency
Place of Performance
Not specifiedSet-Aside
Timeline
Response Deadline
Organization & Contact Information
Full Description
This is a Notice of Funding Opportunity (NOFO) for a Limited Competition that will invite application(s) from eligible organization(s) to apply. Please see Section III. Eligibility for additional information. In accordance with NIH standard peer-review processes, the application(s) will be peer-reviewed, and only meritorious application(s) will be considered for funding. Through this limited competition Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) solicits applications to support continuation of two biospecimen banking resources.
The National Clinical Trials Network (NCTN) Biospecimen Banks (NCTN Biobanks) support the NCI-funded NCTN and the Community Oncology Research Program (NCORP), and The Early-Phase and Experimental Clinical Trials Biospecimen Bank (EET Biobank) supports the Experimental Therapeutics Clinical Trials Network (ETCTN) and other NCI-supported early phase and experimental clinical trials.
The objective is to maintain these national resources for the collection, processing, storage, and distribution of high-quality, clinically annotated human biospecimens. The goal of these resources is to ensure the availability of biospecimens from participants in NCI-funded clinical trials focused on treatment, prevention, and cancer control studies to enable translational cancer research.
The NCTN Biobanks support biomarker development and validation, secondary correlative studies, and broader scientific discovery using biospecimens collected through harmonized protocols and linked to clinical outcome data from large multi-site clinical trials.
The EET Biobank supports biospecimen banking for ETCTN and other early-phase and experimental therapeutic clinical trials involving investigational agents. Biospecimens collected through these studies support biomarker assay development, pharmacokinetic and pharmacodynamic analyses, investigation of drug response and resistance mechanisms, patient stratification, and translational research supporting development of novel cancer therapies. In accordance with NIH standard peer-review processes, the application(s) will be peer-reviewed, and only meritorious application(s) will be considered for funding.
Similar Contracts
Same NAICS industry code
Ready to Pursue This Opportunity?
Get AI-powered intelligence on this solicitation and the ones like it
Every page of the solicitation package shredded into a compliance breakdown
AI-powered matching based on your capabilities and past performance
Competitor and incumbent history on the requirement
Automated alerts on amendments, Q&A deadlines, and award
Join 750+ contractors already using CLEATUS
